A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database.

Medicine (Baltimore) · 2026 · PMC13200933 · PMID 42175505

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In the PT level classification, based on the ranking of ROR values, anlotinib’s anaphylactoid reaction (ROR = 128.35, 95% CI = 34.44–478.27, PRR = 128.14, χ 2 = 280.34, EBGM = 71.63, EBGM05 = 23.83, IC = 6.16, IC025 = 4.58) demonstrated a highly significant positive signal, suggesting a potential safety signal worthy of further investigation.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.